Willingness-to-pay and quality of life in patients with vitiligo

British Journal of Dermatology

Volumn 161, Issue 1, 2009, Pages 134-139

  Radtke, M A ^a   Schafer I ^a   Gajur, A ^a   Langenbruch, A ^a   Augustin, M ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Dermatology Life Quality Index; Health care; Quality of life; Vitiligo; Willingness to pay

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CORRELATION ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PARAMETER; PATIENT ATTITUDE; PRIORITY JOURNAL; PSORIASIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUALITY OF LIFE INDEX; QUESTIONNAIRE; REMISSION; SCHOOL CHILD; SCORING SYSTEM; SEX DIFFERENCE; VITILIGO; WELLBEING; WILLINGNESS TO PAY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEES AND CHARGES; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; VITILIGO; YOUNG ADULT;

EID: 67649921373     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09091.x     Document Type: Article

References (42)

1. Hahn SK, Nordlund JJ. Vitiligo. Oxford : Blackwell Science, 2000.
2. Ortonne JP, Mosher DB, Fitzpatrick TB. Disorders with circumscript melanosis. In : Vitiligo and other Hypomelanoses of Hair and Skin (Ortonne JP, Mosher DB, Fitzpatrick TB, eds). New York : Plenum Medical Book Co., 1983 182 222.
3. Ongenae K, van Geel N, De Schepper S, Naeyaert JM. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol 2005 152 : 1165 72.
4. Belhadjali H, Amri M, Mecheri A et al. Vitiligo and quality of life: a case control study. Ann Dermatol Venereol 2007 134 : 233 6.
5. Sampogna F, Raskovic D, Guerra L et al. Identification of categories at risk for high quality of life impairment in patients with vitiligo. Br J Dermatol 2008 159 : 351 9.
6. Linthorst Homan MW, Mirjam AG, Sprangers MS et al. Characteristics of patients with universal vitiligo and health-related quality of life. Arch Dermatol 2008 144 : 1062 4.
7. Ongenae K, Dierckxsens L, Brochez L et al. Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology 2005 210 : 279 85.
8. Borimnejad L, Parsa Yekta Z, Nikbakht-Nasrabadi A, Firooz A. Quality of life with vitiligo: comparison of male and female Muslim patients in Iran. Gend Med 2006 3 : 124 30.
9. Augustin M, Gajur AI, Reich C et al. Benefit evaluation in vitiligo treatment: development and validation of a patient-defined outcome questionnaire. Dermatology 2008 217 : 101 6.
10. Jowett S, Ryan T. Skin disease and handicap: an analysis of the impact of skin conditions. Soc Sci Med 1985 20 : 425 9.
11. Porter JR, Beuf AH, Nordlund JJ, Lerner AB. Psychological reaction to chronic skin disorders: a study of patients with vitiligo. Gen Hosp Psychiatry 1979 1 : 73 7.
12. Firooz A, Bouzari N, Fallah N et al. What patients with vitiligo believe about their condition. Int J Dermatol 2004 43 : 811 14.
13. Porter JR, Beuf AH, Lerner AB, Nordlund JJ. The effect of vitiligo on sexual relationships. J Am Acad Dermatol 1990 22 : 221 2.
14. Porter JR, Beuf AH, Nordlund JJ, Lerner AB. Personal responses to vitiligo: the importance of the patient-physician interaction. Arch Dermatol 1978 114 : 1348 85.
15. Mattoo SK, Handa S, Kaur I et al. Psychiatric morbidity in vitiligo: prevalence and correlates in India. J Eur Acad Dermatol Venereol 2002 16 : 573 8.
16. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19 : 210 16.
17. EuroQol Group. EuroQol - a new facility for the measurement of health related quality of life. Health Policy 1990 16 : 199 208.
18. O'Brien B, Gafni A. When do the 'dollars' make sense? Toward a conceptual framework for contingent valuation studies in health care. Med Decis Making 1996 16 : 288 99.
19. Schmitt J, Meurer M, Klon M, Frick KD. Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol 2008 158 : 351 9.
20. Cham PM, Chen SC, Grill JP et al. Reliability of self-reported willingness-to-pay and annual income in patients treated for toenail onychomycosis. Br J Dermatol 2007 156 : 922 8.
21. Schiffner R, Schiffner-Rohe J, Gerstenhauer M et al. Willingness-to-pay and time-trade-off: sensitive to changes of quality of life in psoriasis patients? Br J Dermatol 2003 148 : 1153 60.
22. Schiffner R, Brunnberg S, Hohenleutner U et al. Willingness to pay and time trade-off: useful utility indicators for the assessment of quality of life and patient satisfaction in patients with port wine stains. Br J Dermatol 2002 146 : 440 7.
23. Poyner TF, Menday AP, Williams ZV. Patient attitudes to topical antipsoriatic treatment with calcipotriol and dithranol. J Eur Acad Dermatol Venereol 2000 14 : 153 8.
24. Rychlik R, Wertheimer A, Rusche H et al. Policy decision making and outcomes research in drug utilization. Z Gesundheitswiss/J Public Health 2005 1 : 1 14.
25. Zentner A, Velasco-Garrido M, Busse R. Methods for the comparative evaluation of pharmaceuticals. GMS Health Technol Assess 1: Doc09, 2005. Available at: http://www.egms.de/en/journals/hta/2005-1/hta000009.shtml (last accessed 8 January 2009).
26. Stangier U, Ehlers A, Gieler U. Fragebogen zur Bewältigung von Hautkrankheiten (FBH). Handanweisung. Göttingen : Hogrefe, 1996.
27. Augustin M, Zschocke I, Lange S et al. Quality of life in skin diseases: methodological and practical comparison of different quality of life questionnaires in psoriasis and atopic dermatitis. Hautarzt 1999 50 : 715 22.
28. Thompson MS, Read JL, Liang M. Feasibility of willingness-to-pay in arthritis. Med Decis Making 1984 4 : 195 215.
29. Augustin M, Krüger K, Radtke MA et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter prospective cross-sectional study in Germany. Dermatology 2008 216 : 366 72.
30. Salzer BA, Schallreuter KU. Investigation of the personality structure in patients with vitiligo and a possible association with impaired catecholamine metabolism. Dermatology 1995 190 : 109 15.
31. Kent G, Al-Abadie M. Factors affecting responses on Dermatology Life Quality Index items among vitiligo sufferers. Clin Exp Dermatol 1996 21 : 330 3.
32. Alkhateeb A, Fain PR, Thody A et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 2003 16 : 208 14.
33. Hartmann A, Lurz C, Hamm H et al. Narrow-band UVB 312 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol 2005 44 : 736 42.
34. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000 42 : 245 53.
35. Parsad D, Pandhi R, Dogra S et al. Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome. Br J Dermatol 2003 148 : 373 4.
36. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995 132 : 236 44.
37. Lachaine J, Laurier C, Contandriopoulos AP. Defining monetary values for quality of life improvements: an exploratory study. Pharmacoeconomics 2003 21 : 865 74.
38. Lundberg L, Johannesson M, Silverdahl M et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999 141 : 1067 75.
39. Revicki D, Willian MK, Saurat JH et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008 158 : 549 57.
40. Shikiar R, Willian MK, Okun MM et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006 4 : 71.
41. Weiss SC, Nguyen J, Chon S, Kimball AB. A randomized controlled clinical trial assessing the effect of betamethasone valerate 0·12% foam on the short-term treatment of stasis dermatitis. J Drugs Dermatol 2005 4 : 339 45.
42. van den Hout WB, de Jong Z, Munneke M et al. Cost-utility and cost-effectiveness analyses of a long-term, high-intensity exercise program compared with conventional physical therapy in patients with rheumatoid arthritis. Arthritis Care Res 2005 53 : 39 47. (Pubitemid 40216350)